Journal
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
Volume 66, Issue 4, Pages -Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/aac.02179-21
Keywords
KPC; carbapenemase
Categories
Funding
- Antimicrobial Resistance Cross Council Initiative [MR/S004769/1]
- National Institute for Health Research
- University of Bristol
Ask authors/readers for more resources
The study reveals a variant of Klebsiella pneumoniae that exhibits resistance to multiple antibiotics, including ceftazidime-avibactam and meropenem-vaborbactam. Further mutations and enzyme production are required for resistance to other antibiotics.
We show that a previously described Klebsiella pneumoniae variant that is resistant to ceftazidime-avibactam plus meropenem-vaborbactam, has a ramR plus ompK36 mutation, and produces the V239G variant KPC-3 (V240G per the standard numbering system) exhibits resistance to ceftazidime-avibactam plus aztreonam and imipenem-relebactam but not cefepime-taniborbactam. The V239G variant does not generate collateral beta-lactam susceptibility like many KPC-3 variants associated with ceftazidime-avibactam resistance. Additional mutation of ompK35 and production of the OXA-48-like carbapenemase OXA-232 were required to confer cefepime-taniborbactam resistance.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available